APA (7th ed.) Citation

Zanetta, C., Gasperini, C., Amato, M. P., Centonze, D., Gallo, P., Patti, F., . . . Filippi, M. (2025). Potential use of the SARS-CoV-2 monoclonal antibody sipavibart in people with multiple sclerosis: Definition of different patient archetypes from an Italian expert group perspective. Journal of neurology, 272(7), 446. https://doi.org/10.1007/s00415-025-13188-9

Chicago Style (17th ed.) Citation

Zanetta, Chiara, Claudio Gasperini, Maria Pia Amato, Diego Centonze, Paolo Gallo, Francesco Patti, Agostino Riva, and Massimo Filippi. "Potential Use of the SARS-CoV-2 Monoclonal Antibody Sipavibart in People with Multiple Sclerosis: Definition of Different Patient Archetypes from an Italian Expert Group Perspective." Journal of Neurology 272, no. 7 (2025): 446. https://doi.org/10.1007/s00415-025-13188-9.

MLA (9th ed.) Citation

Zanetta, Chiara, et al. "Potential Use of the SARS-CoV-2 Monoclonal Antibody Sipavibart in People with Multiple Sclerosis: Definition of Different Patient Archetypes from an Italian Expert Group Perspective." Journal of Neurology, vol. 272, no. 7, 2025, p. 446, https://doi.org/10.1007/s00415-025-13188-9.